Tyligand Bioscience to Present Preclinical Study Results of TSN1611, a potent, selective, and orally bioavailable KRAS G12D Inhibitor at AACR 2024, following FDA’s IND Clearance

Shanghai, March 20^th, 2024 - Tyligand Bioscience, a clinical-stage biotechnology company dedicated to developing innovative therapeutics against drug resistant tumors, announces its participation at the 2024 American Association for Cancer Research (AACR) Annual Meeting on April 5-10, San Diego, where it will present results of preclinical studies of TSN1611 (Poster# 3315), a potent and selective small molecule inhibitor targeting tumors harboring KRAS G12D mutation, a pivotal driver of cancer progression in numerous malignancies.

On Feb 14^th, an oral formulation of TSN1611 has received clearance from the U.S. Food and Drug Administration (FDA) for clinical trials, an essential step forward in the development of this promising therapy.

"Preclinical studies indicate that TSN1611 has the potential to make a meaningful difference in the lives of patients with KRAS G12D driven cancers, and we are excited to share our findings with the scientific and medical community," said Tony Zhang, Ph.D., CEO of Tyligand Bioscience. "We remain committed to advancing its development with quality and speed for the global cancer patients in need".

KRAS mutations are among the most prevalent oncogenic alterations in cancer patients, with the G12D mutation being one of the most challenging to target effectively. Despite significant advances in cancer research and therapy, KRAS-driven cancers present a substantial unmet medical need, underscoring the urgency for innovative treatment options.

The preclinical data to be presented by Tyligand Bioscience at AACR 2024 demonstrates the promising efficacy and safety profile of TSN1611 in inhibiting KRAS G12D. FDA’s IND approvals marks the achievement of an important milestone in advancing TSN1611 towards clinical evaluations for its safety and efficacy.